Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis

This study aimed to provide information that bedaquilline is significantly effective for treatment of totally drug resistant (TDR) Mycobacterium tuberculosis that shows resistant to all first- and second-line drugs-using an innovative disc agarose channel (DAC) system. Time-lapse images of single bacterial cells under culture conditions with different concentrations of bedaquiline were analysed by image processing software to determine minimum inhibitory concentrations (MICs). Bedaquiline inhibited the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L. The results of the present study demonstrate that bedaquiline, newly approved by the United States Food and Drug Administration (FDA), may offer therapeutic solutions for TDR-TB.

[1]  J. Palomino,et al.  Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. , 2011, FEMS immunology and medical microbiology.

[2]  W. Bishai,et al.  Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.

[3]  D. Zenner,et al.  Multidrug-Resistant Tuberculosis (MDR-TB) , 2018 .

[4]  G. Bloemberg,et al.  Determination of MIC Distribution and Epidemiological Cutoff Values for Bedaquiline and Delamanid in Mycobacterium tuberculosis Using the MGIT 960 System Equipped with TB eXiST , 2015, Antimicrobial Agents and Chemotherapy.

[5]  F. Portaels,et al.  Resazurin Microtiter Assay Plate Testing of Mycobacterium tuberculosis Susceptibilities to Second-Line Drugs: Rapid, Simple, and Inexpensive Method , 2003, Antimicrobial Agents and Chemotherapy.

[6]  Chong-Jen Yu,et al.  Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. , 2013, The Journal of antimicrobial chemotherapy.

[7]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[8]  A. Spanevello,et al.  Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[10]  Avinash Sonawane,et al.  Antimicrobial peptides and proteins in mycobacterial therapy: current status and future prospects. , 2014, Tuberculosis.

[11]  R. Mahajan.  Bedaquiline: First FDA-approved tuberculosis drug in 40 years , 2013, International journal of applied & basic medical research.

[12]  Alimuddin Zumla,et al.  Totally drug‐resistant tuberculosis and adjunct therapies , 2015, Journal of internal medicine.

[13]  M Drancourt,et al.  Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[15]  S. Ryoo,et al.  Rapid drug susceptibility test of Mycobacterium tuberculosis using microscopic time-lapse imaging in an agarose matrix , 2016, Applied Microbiology and Biotechnology.

[16]  J. Tyagi,et al.  Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. , 2007, The Journal of antimicrobial chemotherapy.

[17]  Z. Udwadia,et al.  Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining , 2012, Journal of Epidemiology & Community Health.

[18]  J. C. Lee,et al.  A rapid antimicrobial susceptibility test based on single-cell morphological analysis , 2014, Science Translational Medicine.

[19]  J. Schellens,et al.  Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis , 2014, Antimicrobial Agents and Chemotherapy.

[20]  L. Gabbasova,et al.  Global tuberculosis report (2014) , 2014 .

[21]  Dirk Bald,et al.  Diarylquinolines target subunit c of mycobacterial ATP synthase. , 2007, Nature chemical biology.

[22]  Charles L Daley,et al.  Management of Multidrug-Resistant Tuberculosis , 2013, Seminars in Respiratory and Critical Care Medicine.

[23]  L. Rigouts,et al.  Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. , 2015, The Journal of antimicrobial chemotherapy.